Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 103,211

Document Document Title
WO/2014/170892A1
The present invention provides compositions and methods for treating lysosomal storage disease characterized by elevation of RIP kinase in a subject in need thereof using at least one RIP kinase inhibitor.  
WO/2014/170900A1
Eph A receptor inhibitor peptides, and particularly Eph A4 receptor inhibitor peptides, are provided. The peptides comprise a sequence derived from the G-H loop of ephrin A4. Further, pharmaceutical compositions comprising said peptides ...  
WO/2014/171528A1
[Problem] To provide a compound of formula (I) that is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM). [Solution] The inventors studied a compound that has a dopamine D1 receptor positive allosteric modulating ac...  
WO/2014/170704A1
The invention relates to new morphine derivatives deuterated at the 7,8-position of the morphine ring, furthermore to a process for the preparation thereof, and to pharmaceutical compositions comprising them. The new deuterated morphine ...  
WO/2014/168925A1
Compositions comprising one or more opioids and one or more inhibitors of uridine diphosphate glucuronosyl transferases (UGTs) are provided. The inhibitors decrease the presystemic metabolism of the one or more opioids, thereby increasin...  
WO/2014/168262A1
The invention provides compound (I): wherein each symbol is as defined in the specification, having a tyrosine kinase inhibitory action on Trk receptors such as TrkA, TrkB, TrkC or other tyrosine kinase receptors such as Flt-3, which is ...  
WO/2014/166906A1
The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese...  
WO/2014/168727A1
The present invention relates to a fixed dosage unit, and methods for treating schizophrenia comprising administering the fixed dosage unit. More specifically, the present invention relates to a fixed dosage unit that reduces the inciden...  
WO/2014/168228A1
The purpose of the present invention is to provide a pregabalin-containing composition that can produce satisfactory drug efficacy through topical administration. This composition is characterized in that the composition is one for topic...  
WO/2014/168523A1
The present invention relates to novel biologically active compounds being dicarboxylic acid bisamide derivatives of general formula (I), or pharmaceutically acceptable salts thereof, which are capable of complexing or chelating metal io...  
WO/2014/167439A1
The present invention relates to modified release pharmaceutical compositions of topiramate or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising at least two types of c...  
WO/2014/163150A1
Provided is a composition for internal use, which contains methylthioadenosine and is reduced in bitterness. This composition for internal use contains methylthioadenosine or a salt thereof (component (A)) and S-adenosylmethionine or a s...  
WO/2014/163210A1
A compound selected from the group consisting of compounds represented by the formulas below or pharmaceutically acceptable salt thereof is useful in PET imaging for AMPA receptor.  
WO/2014/163328A1
Provided in the present specification is a composition for brain activation, comprising ginseng berry extract as an active ingredient. The composition according to the present specification allows an increase in blood flow in the brain a...  
WO/2014/162195A1
Novel two-component formulations, procedures and methods for use in treating neuropathology incident to trauma are provided, Two-component formulations of the invention comprise biologically active forms of at least one neurosteroid or n...  
WO/2014/163402A1
The present invention relates to a composition which improves the quality of life of women by containing a ginseng berry extract as an active ingredient and, more specifically, to a composition which promotes the general psychological an...  
WO/2014/162276A1
The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek s...  
WO/2014/163643A1
This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and in...  
WO/2014/165701A1
Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptamine sub-receptor six (5-HT 6) receptor antagonists are provided for improving the cognition o...  
WO/2014/163147A1
The present invention provides a salt produced from at least one acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, malonic acid, maleic acid, tartaric acid, metha...  
WO/2014/163161A1
The present invention pertains to a compound indicated by formula (I), said compound being useful as a prophylactic or treatment agent for epilepsy and neurodegenerative diseases, etc. In the formula (I), each symbol is as defined in the...  
WO/2014/161095A1
Disclosed herein are human CRP40 fragments and polynucleotides encoding them. The CRP40 fragments and polynucleotides may be useful in the treatment of diseases associated with one or more of oxidative stress, mitochondrial dysfunction a...  
WO/2014/161037A1
The present invention relates to antibodies and antigen-binding fragments thereof that bind RYK, in particular human RYK and their use in regulating RYK-associated activities. Specifically there is provided an isolated monoclonal antibod...  
WO/2014/162737A1
Provided is a tau aggregation inhibitor which can satisfactorily inhibit the aggregation of tau in a cell. The tau aggregation inhibitor contains either a 4-substituted catechol structure compound in which an electron-donating group (R) ...  
WO/2014/163152A1
The present invention addresses the problem of providing a novel drug for promoting natural sleep. The solution is a non-REM sleep-promoting agent, deep sleep-promoting agent or natural sleep-inducing agent that has methylthioadenosine o...  
WO/2014/163151A1
The present invention addresses the problem of providing a yeast culture and a composition each having a high methylthioadenosine content; and novel use applications of the yeast culture and the composition. The present invention provide...  
WO/2014/163162A1
The present invention pertains to a compound indicated by formula (I), said compound being useful as a prophylactic or treatment agent for epilepsy and neurodegenerative diseases, etc. In the formula (I), each symbol is as defined in the...  
WO/2014/165070A1
The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or...  
WO/2014/163518A1
The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in preventing the recurrence/relapse of Bipolar Disorder 1 and/or one or more episodes associated with Bipolar Disorder 1 in a human patient.  
WO/2014/163416A1
The present invention relates to a composition for life extension and particularly to a composition for life extension containing syringaresinol. The composition according to the present invention can extend the life of an individual by ...  
WO/2014/164756A1
Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.  
WO/2014/165043A1
The described invention relates to methods for treating, preventing, or diagnosing the pathology of progressive cognitive disorders resulting from accumulation of an amyloid peptide, in particular, Alzheimer's disease, Down's syndrome an...  
WO/2014/163132A1
The present invention addresses the problem of proving a stabilized solid composition of an amino carboxylate salt. The solution is a medicinal solid composition containing [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6 -yl...  
WO/2014/165827A1
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demye...  
WO/2014/165065A1
The present invention is directed to compounds of Formula I: wherein X is CR1 or N; Y is CR2 or N; Z is NH or O; R1 is alkoxy, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, or pyrimidinyl; R2 is H, alkyl, or halo; R3 is H, alkyl, alkoxy,...  
WO/2014/161801A1
The present invention relates to compounds of general formula I wherein R1 is halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or cyano; R2 is hydrogen, CF3 or lower alkyl; R3 is...  
WO/2014/163146A1
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, R1 represents a group represented by formula (II), a group represented by formula (III) or a group represented by formula (IV); and R2 ...  
WO/2014/154895A1
The present invention relates to novel compounds of Formula (I), and their use in therapeutic treatments.  
WO/2014/157437A1
A propellane derivative represented by general formula (I) (wherein R1 represents a hydrogen atom, a C1-6 alkyl group, a cycloalkylalkyl group (wherein the number of carbon atoms in a cycloalkyl moiety is 3 to 6 and the number of carbon ...  
WO/2014/157860A1
The present invention provides a process for the preparation of high-purity olanzapine with high yield and a process for the preparation of olanzapine crystalline Form II, which are industrially applicable. The preparation processes acco...  
WO/2014/154179A1
The present invention discloses compound 2β,3α,5α-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.  
WO/2014/155387A1
The present invention relates to extended release dosage forms of weakly basic drugs. Particularly the present invention is related to extended release dosage forms of quetiapine or pharmaceutically acceptable salts thereof.  
WO/2014/157047A1
The present invention relates to a therapeutic agent for neurodegenerative diseases, which contains a compound represented by formula (I) or a salt thereof. (In the formula, Ar1 represents an aromatic group; X represents a single bond or...  
WO/2014/159662A1
The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biologica...  
WO/2014/158916A1
The invention provides a chemical entity of Formula (I), wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and and their use in a wide range o...  
WO/2014/160811A1
The invention features XIB4035 for the treatment of large fiber neuropathy, and combinations of XIB4035and GDNF for the treatment of both large and small fiber neuropathies.  
WO/2014/157803A1
The present invention relates to a composition for a GABAA-benzodiazepine receptor activation, which includes, as an active ingredient, an extract of at least one shellfish selected from among Mytilus edulis, Tegillarca granosa and Merce...  
WO/2014/160197A1
Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing ...  
WO/2014/154131A1
Provided are a caffeoyl substituted pentacyclic triterpene derivative as represented by formula (I) and pharmaceutical composition containing the same. Also provided are uses of the derivative in the preparation of drugs or health-care p...  
WO/2014/158165A1
A composition for inducing erythropoietin (EPO)-mediated haemoglobin (Hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (I), wherein R is a glycosyl group; and...  

Matches 101 - 150 out of 103,211